Description
BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. BAY 57-1293 has been shown to be a more effective agent than acyclovir (Cat. No. 2200) for treating Alzjeimer’s Disease (AD) by decreasing Aβ and P-tau formation.
BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections.
Alternate Name/Synonyms: N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide
Appearance: White to off-white solid
Formulation: N/A
CAS Number: 348086-71-5
Structure Available?: Y
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₈H₁₈N₄O₃S₂
Molecular Weight: 402.49
Cell-Permeable?: Yes
Purity: ≥95% by HPLC
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A potent helicase primase inhibitor
MDL Number: N/A
PubChem CID: 491941
SMILES: CC1=C(SC(=N1)N(C)C(=O)CC2=CC=C(C=C2)C3=CC=CC=N3)S(=O)(=O)N
InChi: InChI=1S/C18H18N4O3S2/c1-12-17(27(19,24)25)26-18(21-12)22(2)16(23)11-13-6-8-14(9-7-13)15-5-3-4-10-20-15/h3-10H,11H2,1-2H3,(H2,19,24,25)
InChi Key: IVZKZONQVYTCKC-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
24 months |